QuatRx's Ophena positive in Phase III trial of postmenopausal vaginal atrophy
This article was originally published in Scrip
Executive Summary
QuatRx's lead drug candidate, Ophena (ospemifiene), improved symptoms of postmenopausal vaginal atrophy in a second Phase III trial, show top-line data. The private, Michigan-based, company plans to file the drug with the US FDA early next year.